{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:03:02Z","timestamp":1770991382085,"version":"3.50.1"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/142479\/2018"],"award-info":[{"award-number":["SFRH\/BD\/142479\/2018"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["https:\/\/doi.org\/10.54499\/2020.09384.BD"],"award-info":[{"award-number":["https:\/\/doi.org\/10.54499\/2020.09384.BD"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["https:\/\/doi.org\/10.54499\/2022.12980.BD"],"award-info":[{"award-number":["https:\/\/doi.org\/10.54499\/2022.12980.BD"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["https:\/\/doi.org\/10.54499\/SFRH\/BD\/146500\/2019"],"award-info":[{"award-number":["https:\/\/doi.org\/10.54499\/SFRH\/BD\/146500\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["https:\/\/doi.org\/10.54499\/2021.03835.CEECIND\/CP1688\/CT0001"],"award-info":[{"award-number":["https:\/\/doi.org\/10.54499\/2021.03835.CEECIND\/CP1688\/CT0001"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2018.00091.CEECINST"],"award-info":[{"award-number":["2018.00091.CEECINST"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["https:\/\/doi.org\/10.54499\/2020.09394.BD"],"award-info":[{"award-number":["https:\/\/doi.org\/10.54499\/2020.09394.BD"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["https:\/\/doi.org\/10.54499\/2020.08708.BD"],"award-info":[{"award-number":["https:\/\/doi.org\/10.54499\/2020.08708.BD"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2024.04043. BDANA"],"award-info":[{"award-number":["2024.04043. BDANA"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2024.00895.BD"],"award-info":[{"award-number":["2024.00895.BD"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID\/QUI\/50006\/2019 - Laborat\u00f3rio Associado para a Qu\u00edmica Verde Tecnologias e Processos Limpos"],"award-info":[{"award-number":["UID\/QUI\/50006\/2019 - Laborat\u00f3rio Associado para a Qu\u00edmica Verde Tecnologias e Processos Limpos"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["https:\/\/doi.org\/10.54499\/2023.06366.CEECIND\/CP2864\/CT0001"],"award-info":[{"award-number":["https:\/\/doi.org\/10.54499\/2023.06366.CEECIND\/CP2864\/CT0001"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PEst-OE\/SAU\/UI0776\/201, CI-IPOP-29-2016-2022, CI-IPOP-58-2016-2022"],"award-info":[{"award-number":["PEst-OE\/SAU\/UI0776\/201, CI-IPOP-29-2016-2022, CI-IPOP-58-2016-2022"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["https:\/\/doi.org\/10.54499\/2022.08311.CEECIND\/CP1744\/CT0001"],"award-info":[{"award-number":["https:\/\/doi.org\/10.54499\/2022.08311.CEECIND\/CP1744\/CT0001"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Colorectal cancer (CRC) progression is fuelled by immune evasion, yet the underlying molecular mechanisms remain to be fully characterized. CD276 (B7-H3), an immune checkpoint glycoprotein frequently overexpressed in aggressive tumors, is extensively modified by glycosylation, a process known to regulate protein stability, localization, and immune interactions. However, its glycosylation-dependent functions in CRC remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      TCGA Transcriptomic data were analysed to identify glycogene alterations linked to patient prognosis. The O-glycome of advanced CRC and normal mucosa was profiled by mass spectrometry. CD276 expression and glycosylation were examined in primary tumors, lymph nodes, and metastases by immunohistochemistry, proximity ligation assays, and dual immunofluorescence. CRC proteomic datasets from PRIDE (\u2265\u200990 cases) were reanalyzed to map CD276 immature glycosylation across differentiation states.\n                      <jats:italic>C1GALT1<\/jats:italic>\n                      knockout CRC cell lines were generated with CRISPR-Cas9 to mimic immature glycosylation in tumors, and CD276 was silenced with siRNAs. Immunoprecipitation, lectin blotting, protein stability assays, proliferation, invasion, phosphoproteomics, and T cell co-culture experiments were used to assess functional consequences.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Downregulation of\n                      <jats:italic>B3GNT6<\/jats:italic>\n                      and\n                      <jats:italic>C1GALT1<\/jats:italic>\n                      or\n                      <jats:italic>C1GALT1C1<\/jats:italic>\n                      defined an immature O-glycosylation phenotype associated with poor prognosis. Glycomic profiling revealed Tn- and sialyl-Tn(sTn)-enriched glycophenotypes in both epithelial- and mesenchymal-like tumors, with subtype-specific patterns. CD276 colocalized with Tn and sTn, carried immature O-glycans absent from healthy tissues, and was enriched in right-sided and metastatic CRC, correlating with worse survival. PRIDE reanalysis suggested widespread CD276 expression and revealed differentiation-linked glycosylation, which was denser in the IgV and IgC domains of epithelial-like tumors and sparser, membrane-proximal in mesenchymal-like tumors.\n                      <jats:italic>C1GALT1<\/jats:italic>\n                      knockout in CRC cells enhanced invasion while increasing CD276 stability and transcription, driving its overexpression. Aberrantly glycosylated CD276 promoted proliferation, invasion, kinase-driven signalling, and T cell suppression while driving cytokines toward immunosuppression. TCGA confirmed that high\n                      <jats:italic>CD276<\/jats:italic>\n                      and low\n                      <jats:italic>C1GALT1<\/jats:italic>\n                      expression correlated with transcriptional signatures of heightened immune checkpoint activity and T cell exhaustion.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Immature CD276 glycosylation promotes CRC aggressiveness and immune escape, representing a candidate prognostic biomarker and therapeutic target.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                    <jats:p>\n                      Colorectal cancer (CRC) progression is closely linked to immune evasion, yet the molecular mechanisms underlying this process remain poorly understood. This study identifies CD276 (B7-H3) as a glycosylation-driven regulator of CRC aggressiveness and demonstrates how\n                      <jats:italic>O<\/jats:italic>\n                      -glycosylation remodelling promotes tumor immune escape. These findings establish CD276 as a potential therapeutic target and highlight the role of glycoproteoform-specific immune modulation in cancer progression.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12964-026-02672-y","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T10:51:26Z","timestamp":1768906286000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CD276 immature glycosylation drives colorectal cancer aggressiveness and T cell mediated immune escape"],"prefix":"10.1186","volume":"24","author":[{"given":"Janine","family":"Soares","sequence":"first","affiliation":[]},{"given":"Dylan","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Andreia","family":"Miranda","sequence":"additional","affiliation":[]},{"given":"Martina","family":"Gon\u00e7alves","sequence":"additional","affiliation":[]},{"given":"Marta","family":"Relvas-Santos","sequence":"additional","affiliation":[]},{"given":"Andreia","family":"Brand\u00e3o","sequence":"additional","affiliation":[]},{"given":"Paula","family":"Paulo","sequence":"additional","affiliation":[]},{"given":"Sofia","family":"Cotton","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Freitas","sequence":"additional","affiliation":[]},{"given":"Mariana","family":"Magalh\u00e3es","sequence":"additional","affiliation":[]},{"given":"Eduardo","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Beatriz","family":"Marinho-Santos","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds Pedro","family":"Afonso","sequence":"additional","affiliation":[]},{"given":"Andr\u00e9 M. N.","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Palmeira","sequence":"additional","affiliation":[]},{"given":"Francisco","family":"Amado","sequence":"additional","affiliation":[]},{"given":"Andreia","family":"Peixoto","sequence":"additional","affiliation":[]},{"given":"L\u00facio Lara","family":"Santos","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Alexandre","family":"Ferreira","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"issue":"3","key":"2672_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2672_CR2","first-page":"2021","volume":"12","author":"Y Li","year":"2021","unstructured":"Li Y, Ma Y, Wu Z, Zeng F, Song B, Zhang Y, et al. Tumor mutational burden predicting the efficacy of immune checkpoint inhibitors in colorectal cancer: a systematic review and meta-analysis. Front Immunol. 2021;12:2021.","journal-title":"Front Immunol"},{"issue":"19","key":"2672_CR3","doi-asserted-by":"publisher","first-page":"4906","DOI":"10.3390\/cancers13194906","volume":"13","author":"CW Kim","year":"2021","unstructured":"Kim CW, Chon HJ, Kim C. Combination immunotherapies to overcome intrinsic resistance to checkpoint blockade in microsatellite stable colorectal cancer. Cancers (Basel). 2021;13(19):4906.","journal-title":"Cancers (Basel)"},{"key":"2672_CR4","first-page":"2021","volume":"12","author":"WT Zhou","year":"2021","unstructured":"Zhou WT, Jin WL. B7\u2013H3\/CD276: an emerging cancer immunotherapy. Front Immunol. 2021;12:2021.","journal-title":"Front Immunol."},{"issue":"1","key":"2672_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12943-023-01751-9","volume":"22","author":"AA Getu","year":"2023","unstructured":"Getu AA, Tigabu A, Zhou M, Lu J, Fodstad O, Tan M. New frontiers in immune checkpoint B7\u2013H3 (CD276) research and drug development. Mol Cancer. 2023;22(1):43.","journal-title":"Mol Cancer"},{"issue":"4","key":"2672_CR6","first-page":"66","volume":"6","author":"JR Castellanos","year":"2017","unstructured":"Castellanos JR, Purvis IJ, Labak CM, Guda MR, Tsung AJ, Velpula KK, et al. B7\u2013H3 role in the immune landscape of cancer. Am J Clin Exp Immunol. 2017;6(4):66\u201375.","journal-title":"Am J Clin Exp Immunol"},{"issue":"30","key":"2672_CR7","doi-asserted-by":"publisher","first-page":"10277","DOI":"10.1073\/pnas.0805458105","volume":"105","author":"KA Hofmeyer","year":"2008","unstructured":"Hofmeyer KA, Ray A, Zang X. The contrasting role of B7\u2013H3. Proc Natl Acad Sci U S A. 2008;105(30):10277\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"2672_CR8","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1016\/j.febslet.2015.06.037","volume":"589","author":"P Zhang","year":"2015","unstructured":"Zhang P, Yu S, Li H, Liu C, Li J, Lin W, et al. ILT4 drives B7\u2013H3 expression via PI3K\/AKT\/mTOR signalling and ILT4\/B7-H3 co-expression correlates with poor prognosis in non-small cell lung cancer. FEBS Lett. 2015;589(17):2248\u201356.","journal-title":"FEBS Lett"},{"issue":"6","key":"2672_CR9","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1097\/SLA.0b013e3181f1939d","volume":"252","author":"T Arigami","year":"2010","unstructured":"Arigami T, Narita N, Mizuno R, Nguyen L, Ye X, Chung A, et al. B7\u2013h3 ligand expression by primary breast cancer and associated with regional nodal metastasis. Ann Surg. 2010;252(6):1044\u201351.","journal-title":"Ann Surg"},{"issue":"49","key":"2672_CR10","doi-asserted-by":"publisher","first-page":"19458","DOI":"10.1073\/pnas.0709802104","volume":"104","author":"X Zang","year":"2007","unstructured":"Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, et al. B7\u2013H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A. 2007;104(49):19458\u201363.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2672_CR11","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1002\/ijc.27566","volume":"131","author":"VA Ingebrigtsen","year":"2012","unstructured":"Ingebrigtsen VA, Boye K, Tekle C, Nesland JM, Flatmark K, Fodstad O. B7\u2013H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer. Int J Cancer. 2012;131(11):2528\u201336.","journal-title":"Int J Cancer"},{"issue":"1","key":"2672_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12935-015-0195-z","volume":"15","author":"F-b Kang","year":"2015","unstructured":"Kang F-b, Wang L, Jia H-c, Li D, Li H-j, Zhang Y-g, et al. B7\u2013H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2\/STAT3\/Slug signaling pathway. Cancer Cell Int. 2015;15(1):45.","journal-title":"Cancer Cell Int"},{"issue":"6","key":"2672_CR13","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.3748\/wjg.v21.i6.1804","volume":"21","author":"T Zhang","year":"2015","unstructured":"Zhang T, Jiang B, Zou ST, Liu F, Hua D. Overexpression of B7\u2013H3 augments anti-apoptosis of colorectal cancer cells by Jak2-STAT3. World J Gastroenterol. 2015;21(6):1804\u201313.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"2672_CR14","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ccell.2017.03.005","volume":"31","author":"S Seaman","year":"2017","unstructured":"Seaman S, Zhu Z, Saha S, Zhang XM, Yang MY, Hilton MB, et al. Eradication of tumors through simultaneous ablation of CD276\/B7-H3-positive tumor cells and tumor vasculature. Cancer Cell. 2017;31(4):501-15.e8.","journal-title":"Cancer Cell"},{"issue":"1","key":"2672_CR15","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1038\/s41467-021-22618-x","volume":"12","author":"Y Huang","year":"2021","unstructured":"Huang Y, Zhang H-L, Li Z-L, Du T, Chen Y-H, Wang Y, et al. FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer. Nat Commun. 2021;12(1):2672.","journal-title":"Nat Commun"},{"issue":"2","key":"2672_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ccell.2018.01.009","volume":"33","author":"CW Li","year":"2018","unstructured":"Li CW, Lim SO, Chung EM, Kim YS, Park AH, Yao J, et al. Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. Cancer Cell. 2018;33(2):187-201 e10.","journal-title":"Cancer Cell"},{"issue":"7","key":"2672_CR17","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.7150\/ijbs.93806","volume":"20","author":"X Ren","year":"2024","unstructured":"Ren X, Lin S, Guan F, Kang H. Glycosylation targeting: a paradigm shift in cancer immunotherapy. Int J Biol Sci. 2024;20(7):2607\u201321.","journal-title":"Int J Biol Sci"},{"key":"2672_CR18","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3389\/fonc.2024.1389713","volume":"14","author":"H Tian","year":"2024","unstructured":"Tian H, Yu JL, Chu X, Guan Q, Liu J, Liu Y. Unraveling the role of C1GALT1 in abnormal glycosylation and colorectal cancer progression. Front Oncol. 2024;14:2024.","journal-title":"Front Oncol."},{"key":"2672_CR19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/bs.acr.2014.11.004","volume":"126","author":"S Holst","year":"2015","unstructured":"Holst S, Wuhrer M, Rombouts Y. Glycosylation characteristics of colorectal cancer. Adv Cancer Res. 2015;126:203\u201356.","journal-title":"Adv Cancer Res"},{"issue":"1","key":"2672_CR20","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/jcmm.14740","volume":"24","author":"T Gao","year":"2020","unstructured":"Gao T, Du T, Hu X, Dong X, Li L, Wang Y, et al. Cosmc overexpression enhances malignancies in human colon cancer. J Cell Mol Med. 2020;24(1):362\u201370.","journal-title":"J Cell Mol Med"},{"issue":"49","key":"2672_CR21","doi-asserted-by":"publisher","first-page":"41523","DOI":"10.1074\/jbc.M112.371989","volume":"287","author":"R Mi","year":"2012","unstructured":"Mi R, Song L, Wang Y, Ding X, Zeng J, Lehoux S, et al. Epigenetic silencing of the chaperone Cosmc in human leukocytes expressing tn antigen. J Biol Chem. 2012;287(49):41523\u201333.","journal-title":"J Biol Chem"},{"issue":"6","key":"2672_CR22","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1158\/0008-5472.CAN-07-2345","volume":"68","author":"T Ju","year":"2008","unstructured":"Ju T, Lanneau GS, Gautam T, Wang Y, Xia B, Stowell SR, et al. Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer Res. 2008;68(6):1636\u201346.","journal-title":"Cancer Res"},{"key":"2672_CR23","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20191062","author":"J Liu","year":"2020","unstructured":"Liu J, Xu F, Li J, Jiang H. Overexpression of Cosmc suppresses cell migration and invasion in different subtypes of breast cancer cells via Tn and T glycans. 2020. Biosci Rep. https:\/\/doi.org\/10.1042\/BSR20191062."},{"issue":"20","key":"2672_CR24","doi-asserted-by":"publisher","first-page":"9228","DOI":"10.1073\/pnas.0914004107","volume":"107","author":"Y Wang","year":"2010","unstructured":"Wang Y, Ju T, Ding X, Xia B, Wang W, Xia L, et al. Cosmc is an essential chaperone for correct protein O-glycosylation. Proc Natl Acad Sci U S A. 2010;107(20):9228\u201333.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2672_CR25","doi-asserted-by":"publisher","first-page":"511","DOI":"10.2147\/CMAR.S234735","volume":"12","author":"T Du","year":"2020","unstructured":"Du T, Jia X, Dong X, Ru X, Li L, Wang Y, et al. Cosmc Disruption-mediated aberrant O-glycosylation suppresses breast cancer cell growth via impairment of CD44. Cancer Manag Res. 2020;12:511\u201322.","journal-title":"Cancer Manag Res"},{"issue":"5","key":"2672_CR26","doi-asserted-by":"publisher","first-page":"e0125994","DOI":"10.1371\/journal.pone.0125994","volume":"10","author":"R Beatson","year":"2015","unstructured":"Beatson R, Maurstad G, Picco G, Arulappu A, Coleman J, Wandell HH, et al. The breast cancer-associated glycoforms of MUC1, MUC1-Tn and sialyl-Tn, are expressed in COSMC wild-type cells and bind the C-type lectin MGL. PLoS ONE. 2015;10(5):e0125994.","journal-title":"PLoS ONE"},{"issue":"7518","key":"2672_CR27","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nature13438","volume":"513","author":"B Zhang","year":"2014","unstructured":"Zhang B, Wang J, Wang X, Zhu J, Liu Q, Shi Z, et al. Proteogenomic characterization of human colon and rectal cancer. Nature. 2014;513(7518):382\u20137.","journal-title":"Nature"},{"key":"2672_CR28","doi-asserted-by":"crossref","unstructured":"Wickham H AM BJ, Chang W, McGowan LD, Fran\u00e7ois R, Grolemund G, Hayes A, Henry L, Hester J,, Kuhn M PT, Miller E, Bache SM, M\u00fcller K, Ooms J, Robinson D, Seidel DP, Spinu V, Takahashi K,, Vaughan D WC, Woo K, Yutani H. . Welcome to the tidyverse. J Open Source Software. 2019.","DOI":"10.21105\/joss.01686"},{"issue":"7","key":"2672_CR29","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.7150\/thno.67409","volume":"12","author":"C Gaiteiro","year":"2022","unstructured":"Gaiteiro C, Soares J, Relvas-Santos M, Peixoto A, Ferreira D, Paulo P, et al. Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion. Theranostics. 2022;12(7):3150\u201377.","journal-title":"Theranostics"},{"issue":"11","key":"2672_CR30","doi-asserted-by":"publisher","first-page":"e0166120","DOI":"10.1371\/journal.pone.0166120","volume":"11","author":"L Lima","year":"2016","unstructured":"Lima L, Gaiteiro C, Peixoto A, Soares J, Neves M, Santos LL, et al. Reference genes for addressing gene expression of bladder cancer cell models under hypoxia: a step towards transcriptomic studies. PLoS ONE. 2016;11(11):e0166120.","journal-title":"PLoS ONE"},{"key":"2672_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040861","author":"E Fernandes","year":"2020","unstructured":"Fernandes E, Freitas R, Ferreira D, Soares J, Azevedo R, Gaiteiro C, et al. Nucleolin-Sle a glycoforms as E-selectin ligands and potentially targetable biomarkers at the cell surface of gastric cancer cells. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12040861.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2672_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13046-021-01988-6","volume":"40","author":"A Peixoto","year":"2021","unstructured":"Peixoto A, Ferreira D, Azevedo R, Freitas R, Fernandes E, Relvas-Santos M, et al. Glycoproteomics identifies HOMER3 as a potentially targetable biomarker triggered by hypoxia and glucose deprivation in bladder cancer. J Exp Clin Cancer Res. 2021;40(1):191.","journal-title":"J Exp Clin Cancer Res"},{"key":"2672_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26104891","author":"M Relvas-Santos","year":"2025","unstructured":"Relvas-Santos M, Ferreira D, Brandao A, Afonso LP, Santos LL, Silva AMN, et al. Glycomics and glycoproteomics reveal distinct oligomannose carriers across bladder cancer stages. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26104891.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2672_CR34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nmeth.3675","volume":"13","author":"MR Kudelka","year":"2016","unstructured":"Kudelka MR, Antonopoulos A, Wang Y, Duong DM, Song X, Seyfried NT, et al. Cellular O-Glycome Reporter\/Amplification to explore O-glycans of living cells. Nat Methods. 2016;13(1):81\u20136.","journal-title":"Nat Methods"},{"issue":"11","key":"2672_CR35","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","volume":"21","author":"J Guinney","year":"2015","unstructured":"Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350\u20136.","journal-title":"Nat Med"},{"issue":"2","key":"2672_CR36","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1158\/1078-0432.CCR-16-0680","volume":"23","author":"A Trinh","year":"2017","unstructured":"Trinh A, Trumpi K, De Sousa EMF, Wang X, de Jong JH, Fessler E, et al. Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry. Clin Cancer Res. 2017;23(2):387\u201398.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2672_CR37","doi-asserted-by":"publisher","first-page":"4498","DOI":"10.7150\/thno.72818","volume":"12","author":"K Maduni\u0107","year":"2022","unstructured":"Maduni\u0107 K, Mayboroda OA, Zhang T, Weber J, Boons GJ, Morreau H, et al. Specific (sialyl-)lewis core 2 o-glycans differentiate colorectal cancer from healthy colon epithelium. Theranostics. 2022;12(10):4498\u2013512.","journal-title":"Theranostics"},{"key":"2672_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9121932","author":"H Hong","year":"2021","unstructured":"Hong H, Benveniste EN. The immune regulatory role of protein kinase CK2 and its implications for treatment of cancer. Biomedicines. 2021. https:\/\/doi.org\/10.3390\/biomedicines9121932.","journal-title":"Biomedicines"},{"issue":"16","key":"2672_CR39","doi-asserted-by":"publisher","first-page":"5417","DOI":"10.1128\/MCB.21.16.5417-5425.2001","volume":"21","author":"RN Bhattacharjee","year":"2001","unstructured":"Bhattacharjee RN, Banks GC, Trotter KW, Lee HL, Archer TK. Histone H1 phosphorylation by Cdk2 selectively modulates mouse mammary tumor virus transcription through chromatin remodeling. Mol Cell Biol. 2001;21(16):5417\u201325.","journal-title":"Mol Cell Biol"},{"key":"2672_CR40","doi-asserted-by":"publisher","first-page":"680071","DOI":"10.3389\/fimmu.2021.680071","volume":"12","author":"M Fazil","year":"2021","unstructured":"Fazil M, Prasannan P, Wong BHS, Kottaiswamy A, Salim N, Sze SK, et al. GSK3\u03b2 interacts with CRMP2 and Notch1 and controls T-cell motility. Front Immunol. 2021;12:680071.","journal-title":"Front Immunol"},{"issue":"7","key":"2672_CR41","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41416-021-01616-2","volume":"126","author":"SW Strum","year":"2022","unstructured":"Strum SW, Gyenis L, Litchfield DW. CSNK2 in cancer: pathophysiology and translational applications. Br J Cancer. 2022;126(7):994\u20131003.","journal-title":"Br J Cancer"},{"issue":"5","key":"2672_CR42","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1083\/jcb.200912135","volume":"190","author":"DH Larsen","year":"2010","unstructured":"Larsen DH, Poinsignon C, Gudjonsson T, Dinant C, Payne MR, Hari FJ, et al. The chromatin-remodeling factor CHD4 coordinates signaling and repair after DNA damage. J Cell Biol. 2010;190(5):731\u201340.","journal-title":"J Cell Biol"},{"issue":"2","key":"2672_CR43","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00018-020-03599-4","volume":"78","author":"S Bahl","year":"2021","unstructured":"Bahl S, Seto E. Regulation of histone deacetylase activities and functions by phosphorylation and its physiological relevance. Cell Mol Life Sci. 2021;78(2):427\u201345.","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"2672_CR44","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s10555-014-9525-1","volume":"33","author":"RA Wang","year":"2014","unstructured":"Wang RA. MTA1\u2013a stress response protein: a master regulator of gene expression and cancer cell behavior. Cancer Metastasis Rev. 2014;33(4):1001\u20139.","journal-title":"Cancer Metastasis Rev"},{"issue":"9","key":"2672_CR45","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/cm.20296","volume":"65","author":"AG Ammer","year":"2008","unstructured":"Ammer AG, Weed SA. Cortactin branches out: roles in regulating protrusive actin dynamics. Cell Motil Cytoskeleton. 2008;65(9):687\u2013707.","journal-title":"Cell Motil Cytoskeleton"},{"key":"2672_CR46","doi-asserted-by":"publisher","first-page":"9110","DOI":"10.12659\/MSM.911523","volume":"24","author":"Y Wang","year":"2018","unstructured":"Wang Y, Yang Q, Cheng Y, Gao M, Kuang L, Wang C. Myosin heavy chain 10 (MYH10) gene silencing reduces cell migration and invasion in the glioma cell lines U251, T98G, and SHG44 by inhibiting the Wnt\/\u03b2-catenin pathway. Med Sci Monit. 2018;24:9110\u20139.","journal-title":"Med Sci Monit"},{"key":"2672_CR47","doi-asserted-by":"publisher","DOI":"10.3892\/or.2024.8776","author":"Q Zeng","year":"2024","unstructured":"Zeng Q, Jiang T, Wang J. Role of LMO7 in cancer (Review). Oncol Rep. 2024. https:\/\/doi.org\/10.3892\/or.2024.8776.","journal-title":"Oncol Rep"},{"issue":"20","key":"2672_CR48","doi-asserted-by":"publisher","first-page":"17873","DOI":"10.18632\/oncotarget.4286","volume":"6","author":"P Indovina","year":"2015","unstructured":"Indovina P, Pentimalli F, Casini N, Vocca I, Giordano A. Rb1 dual role in proliferation and apoptosis: cell fate control and implications for cancer therapy. Oncotarget. 2015;6(20):17873\u201390.","journal-title":"Oncotarget"},{"issue":"1","key":"2672_CR49","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/emboj\/18.1.188","volume":"18","author":"R Wisdom","year":"1999","unstructured":"Wisdom R, Johnson RS, Moore C. C-jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J. 1999;18(1):188\u201397.","journal-title":"EMBO J"},{"key":"2672_CR50","doi-asserted-by":"publisher","first-page":"436307","DOI":"10.1155\/2013\/436307","volume":"2013","author":"D Wu","year":"2013","unstructured":"Wu D, Wu P, Huang Q, Liu Y, Ye J, Huang J. Interleukin-17: a promoter in colorectal cancer progression. Clin Dev Immunol. 2013;2013:436307.","journal-title":"Clin Dev Immunol"},{"issue":"15","key":"2672_CR51","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-2463","volume":"22","author":"C Alfaro","year":"2016","unstructured":"Alfaro C, Teijeira A, O\u00f1ate C, P\u00e9rez G, Sanmamed MF, Andueza MP, et al. Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs). Clin Cancer Res. 2016;22(15):3924\u201336.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2672_CR52","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/1521-4141(200006)30:6<1683::AID-IMMU1683>3.0.CO;2-A","volume":"30","author":"A Joss","year":"2000","unstructured":"Joss A, Akdis M, Faith A, Blaser K, Akdis CA. IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway. Eur J Immunol. 2000;30(6):1683\u201390.","journal-title":"Eur J Immunol"},{"issue":"1","key":"2672_CR53","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","volume":"8","author":"D Jorgovanovic","year":"2020","unstructured":"Jorgovanovic D, Song M, Wang L, Zhang Y. Roles of IFN-\u03b3 in tumor progression and regression: a review. Biomark Res. 2020;8(1):49.","journal-title":"Biomark Res"},{"issue":"10","key":"2672_CR54","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20100643","volume":"207","author":"K Sakuishi","year":"2010","unstructured":"Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207(10):2187\u201394.","journal-title":"J Exp Med"},{"issue":"6","key":"2672_CR55","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s10719-021-10003-1","volume":"38","author":"M Kotsias","year":"2021","unstructured":"Kotsias M, Madunic K, Nicolardi S, Kozak RP, Gardner RA, Jansen BC, et al. A semi-automated, high throughput approach for O-glycosylation profiling of in vitro established cancer cell lines by MALDI-FT-ICR MS. Glycoconj J. 2021;38(6):747\u201356.","journal-title":"Glycoconj J"},{"issue":"1","key":"2672_CR56","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00018-020-03504-z","volume":"78","author":"K Maduni\u0107","year":"2021","unstructured":"Maduni\u0107 K, Zhang T, Mayboroda OA, Holst S, Stavenhagen K, Jin C, et al. Colorectal cancer cell lines show striking diversity of their O-glycome reflecting the cellular differentiation phenotype. Cell Mol Life Sci. 2021;78(1):337\u201350.","journal-title":"Cell Mol Life Sci"},{"issue":"39","key":"2672_CR57","doi-asserted-by":"publisher","first-page":"E4066","DOI":"10.1073\/pnas.1406619111","volume":"111","author":"P Radhakrishnan","year":"2014","unstructured":"Radhakrishnan P, Dabelsteen S, Madsen FB, Francavilla C, Kopp KL, Steentoft C, et al. Immature truncated O-glycophenotype of cancer directly induces oncogenic features. Proc Natl Acad Sci U S A. 2014;111(39):E4066\u201375.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2672_CR58","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.2741\/3909","volume":"16","author":"CA St Hill","year":"2011","unstructured":"St Hill CA. Interactions between endothelial selectins and cancer cells regulate metastasis. Front Biosci (Landmark Ed). 2011;16(9):3233\u201351.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"1","key":"2672_CR59","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1186\/s12885-018-4708-8","volume":"18","author":"X Sun","year":"2018","unstructured":"Sun X, Ju T, Cummings RD. Differential expression of Cosmc, T-synthase and mucins in Tn-positive colorectal cancers. BMC Cancer. 2018;18(1):827.","journal-title":"BMC Cancer"},{"issue":"22","key":"2672_CR60","doi-asserted-by":"publisher","first-page":"e2211087120","DOI":"10.1073\/pnas.2211087120","volume":"120","author":"F Erger","year":"2023","unstructured":"Erger F, Aryal RP, Reusch B, Matsumoto Y, Meyer R, Zeng J, et al. Germline C1GALT1C1 mutation causes a multisystem chaperonopathy. Proc Natl Acad Sci. 2023;120(22):e2211087120.","journal-title":"Proc Natl Acad Sci"},{"key":"2672_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/biom12121732","author":"T Xiang","year":"2022","unstructured":"Xiang T, Qiao M, Xie J, Li Z, Xie H. Emerging roles of the unique molecular chaperone Cosmc in the regulation of health and disease. Biomolecules. 2022. https:\/\/doi.org\/10.3390\/biom12121732.","journal-title":"Biomolecules"},{"issue":"7","key":"2672_CR62","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1158\/1535-7163.MCT-16-0761","volume":"16","author":"L Ni","year":"2017","unstructured":"Ni L, Dong C. New B7 family checkpoints in human cancers. Mol Cancer Ther. 2017;16(7):1203\u201311.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2672_CR63","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1038\/s41467-025-58740-3","volume":"16","author":"Y Huang","year":"2025","unstructured":"Huang Y, Zhong WQ, Yang XY, Shan JL, Zhou L, Li ZL, et al. Targeting site-specific N-glycosylated B7H3 induces potent antitumor immunity. Nat Commun. 2025;16(1):3546.","journal-title":"Nat Commun"},{"issue":"2","key":"2672_CR64","doi-asserted-by":"publisher","first-page":"111758","DOI":"10.1016\/j.isci.2025.111758","volume":"28","author":"A Peixoto","year":"2025","unstructured":"Peixoto A, Ferreira D, Miranda A, Relvas-Santos M, Freitas R, Veth TS, et al. Multilevel plasticity and altered glycosylation drive aggressiveness in hypoxic and glucose-deprived bladder cancer cells. iScience. 2025;28(2):111758.","journal-title":"iScience"},{"issue":"32","key":"2672_CR65","doi-asserted-by":"publisher","first-page":"24600","DOI":"10.1074\/jbc.M110.134544","volume":"285","author":"Y-X Xu","year":"2010","unstructured":"Xu Y-X, Liu L, Caffaro CE, Hirschberg CB. Inhibition of Golgi apparatus glycosylation causes endoplasmic reticulum stress and decreased protein synthesis *. J Biol Chem. 2010;285(32):24600\u20138.","journal-title":"J Biol Chem"},{"issue":"5","key":"2672_CR66","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1128\/MCB.17.5.2550","volume":"17","author":"I Han","year":"1997","unstructured":"Han I, Kudlow JE. Reduced o glycosylation of Sp1 is associated with increased proteasome susceptibility. Mol Cell Biol. 1997;17(5):2550\u20138.","journal-title":"Mol Cell Biol"},{"key":"2672_CR67","doi-asserted-by":"publisher","first-page":"110277","DOI":"10.1016\/j.cellsig.2022.110277","volume":"93","author":"Y Fu","year":"2022","unstructured":"Fu Y, Ning L, Feng J, Yu X, Guan F, Li X. Dynamic regulation of O-GlcNAcylation and phosphorylation on STAT3 under hypoxia-induced EMT. Cell Signal. 2022;93:110277.","journal-title":"Cell Signal"},{"issue":"12","key":"2672_CR68","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1038\/s44318-024-00111-7","volume":"43","author":"Z Liu","year":"2024","unstructured":"Liu Z, Ajit K, Wu Y, Zhu W-G, Gullerova M. The GATAD2B-NuRD complex drives DNA:RNA hybrid-dependent chromatin boundary formation upon DNA damage. EMBO J. 2024;43(12):2453\u201385.","journal-title":"EMBO J"},{"issue":"1","key":"2672_CR69","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/febs.16112","volume":"289","author":"M Sharifi Tabar","year":"2022","unstructured":"Sharifi Tabar M, Giardina C, Feng Y, Francis H, Moghaddas Sani H, Low JKK, et al. Unique protein interaction networks define the chromatin remodelling module of the NuRD complex. FEBS J. 2022;289(1):199\u2013214.","journal-title":"FEBS J"},{"issue":"3","key":"2672_CR70","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","volume":"169","author":"BD Manning","year":"2017","unstructured":"Manning BD, Toker A. AKT\/PKB signaling: navigating the network. Cell. 2017;169(3):381\u2013405.","journal-title":"Cell"},{"issue":"6","key":"2672_CR71","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1158\/0008-5472.CAN-15-1941","volume":"76","author":"CW Li","year":"2016","unstructured":"Li CW, Xia W, Lim SO, Hsu JL, Huo L, Wu Y, et al. AKT1 inhibits epithelial-to-mesenchymal transition in breast cancer through phosphorylation-dependent Twist1 degradation. Cancer Res. 2016;76(6):1451\u201362.","journal-title":"Cancer Res"},{"issue":"Pt 3","key":"2672_CR72","first-page":"745","volume":"126","author":"M Higuchi","year":"2013","unstructured":"Higuchi M, Kihara R, Okazaki T, Aoki I, Suetsugu S, Gotoh Y. Akt1 promotes focal adhesion disassembly and cell motility through phosphorylation of FAK in growth factor-stimulated cells. J Cell Sci. 2013;126(Pt 3):745\u201355.","journal-title":"J Cell Sci"},{"issue":"11\u201312","key":"2672_CR73","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1007\/s00018-009-9154-y","volume":"66","author":"JH Trembley","year":"2009","unstructured":"Trembley JH, Wang G, Unger G, Slaton J, Ahmed K. Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell Mol Life Sci. 2009;66(11\u201312):1858\u201367.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"2672_CR74","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41392-021-00567-7","volume":"6","author":"C Borgo","year":"2021","unstructured":"Borgo C, D\u2019Amore C, Sarno S, Salvi M, Ruzzene M. Protein kinase CK2: a potential therapeutic target for diverse human diseases. Signal Transduct Target Ther. 2021;6(1):183.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"2672_CR75","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S0960-9822(01)00098-7","volume":"11","author":"AM Weaver","year":"2001","unstructured":"Weaver AM, Karginov AV, Kinley AW, Weed SA, Li Y, Parsons JT, et al. Cortactin promotes and stabilizes Arp2\/3-induced actin filament network formation. Curr Biol. 2001;11(5):370\u20134.","journal-title":"Curr Biol"},{"issue":"Pt 7","key":"2672_CR76","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1242\/jcs.093781","volume":"125","author":"SM MacGrath","year":"2012","unstructured":"MacGrath SM, Koleske AJ. Cortactin in cell migration and cancer at a glance. J Cell Sci. 2012;125(Pt 7):1621\u20136.","journal-title":"J Cell Sci"},{"issue":"14","key":"2672_CR77","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.cub.2005.06.043","volume":"15","author":"NS Bryce","year":"2005","unstructured":"Bryce NS, Clark ES, Leysath JML, Currie JD, Webb DJ, Weaver AM. Cortactin promotes cell motility by enhancing lamellipodial persistence. Curr Biol. 2005;15(14):1276\u201385.","journal-title":"Curr Biol"},{"issue":"2","key":"2672_CR78","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.pharmthera.2014.02.012","volume":"143","author":"GH Eom","year":"2014","unstructured":"Eom GH, Kook H. Posttranslational modifications of histone deacetylases: implications for cardiovascular diseases. Pharmacol Ther. 2014;143(2):168\u201380.","journal-title":"Pharmacol Ther"},{"issue":"18","key":"2672_CR79","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1038\/emboj.2010.188","volume":"29","author":"SE Polo","year":"2010","unstructured":"Polo SE, Kaidi A, Baskcomb L, Galanty Y, Jackson SP. Regulation of DNA-damage responses and cell-cycle progression by the chromatin remodelling factor CHD4. EMBO J. 2010;29(18):3130\u20139.","journal-title":"EMBO J"},{"issue":"1","key":"2672_CR80","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1021\/cb500846u","volume":"10","author":"J Fan","year":"2015","unstructured":"Fan J, Krautkramer KA, Feldman JL, Denu JM. Metabolic regulation of histone post-translational modifications. ACS Chem Biol. 2015;10(1):95\u2013108.","journal-title":"ACS Chem Biol"},{"key":"2672_CR81","doi-asserted-by":"publisher","first-page":"107692","DOI":"10.1016\/j.pharmthera.2020.107692","volume":"219","author":"K Fousek","year":"2021","unstructured":"Fousek K, Horn LA, Palena C. Interleukin-8: a chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression. Pharmacol Ther. 2021;219:107692.","journal-title":"Pharmacol Ther"},{"issue":"8","key":"2672_CR82","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1172\/JCI68395","volume":"123","author":"BM Carreno","year":"2013","unstructured":"Carreno BM, Becker-Hapak M, Huang A, Chan M, Alyasiry A, Lie WR, et al. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Invest. 2013;123(8):3383\u201394.","journal-title":"J Clin Invest"},{"issue":"5","key":"2672_CR83","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1158\/2326-6066.CIR-18-0505","volume":"7","author":"Q Haas","year":"2019","unstructured":"Haas Q, Boligan KF, Jandus C, Schneider C, Simillion C, Stanczak MA, et al. Siglec-9 regulates an effector memory CD8(+) T-cell subset that congregates in the melanoma tumor microenvironment. Cancer Immunol Res. 2019;7(5):707\u201318.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"2672_CR84","doi-asserted-by":"publisher","first-page":"105579","DOI":"10.1016\/j.jbc.2023.105579","volume":"300","author":"N Stewart","year":"2024","unstructured":"Stewart N, Daly J, Drummond-Guy O, Krishnamoorthy V, Stark JC, Riley NM, et al. The glycoimmune checkpoint receptor Siglec-7 interacts with T-cell ligands and regulates T-cell activation. J Biol Chem. 2024;300(2):105579.","journal-title":"J Biol Chem"},{"issue":"12","key":"2672_CR85","doi-asserted-by":"publisher","first-page":"5659","DOI":"10.4049\/jimmunol.1202313","volume":"189","author":"N Chunder","year":"2012","unstructured":"Chunder N, Wang L, Chen C, Hancock WW, Wells AD. Cyclin-dependent kinase 2 controls peripheral immune tolerance. J Immunol. 2012;189(12):5659\u201366.","journal-title":"J Immunol"},{"issue":"6","key":"2672_CR86","doi-asserted-by":"publisher","first-page":"e631","DOI":"10.1002\/iid3.631","volume":"10","author":"Y Ma","year":"2022","unstructured":"Ma Y, Liu L, Li B, Wang W, Zhao T. Cdk2 suppresses IL-23 expression and the onset of severe acute pancreatitis. Immunity Inflamm Dis. 2022;10(6):e631.","journal-title":"Immunity Inflamm Dis"},{"key":"2672_CR87","doi-asserted-by":"publisher","first-page":"841716","DOI":"10.3389\/fimmu.2022.841716","volume":"13","author":"C Ripamonti","year":"2022","unstructured":"Ripamonti C, Spadotto V, Pozzi P, Stevenazzi A, Vergani B, Marchini M, et al. Hdac inhibition as potential therapeutic strategy to restore the deregulated immune response in severe COVID-19. Front Immunol. 2022;13:841716.","journal-title":"Front Immunol"},{"key":"2672_CR88","doi-asserted-by":"publisher","first-page":"117295","DOI":"10.1016\/j.biopha.2024.117295","volume":"179","author":"SY Zhang","year":"2024","unstructured":"Zhang SY, Zhang LY, Wen R, Yang N, Zhang TN. Histone deacetylases and their inhibitors in inflammatory diseases. Biomed Pharmacother. 2024;179:117295.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"2672_CR89","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","volume":"27","author":"F Kontos","year":"2021","unstructured":"Kontos F, Michelakos T, Kurokawa T, Sadagopan A, Schwab JH, Ferrone CR, et al. B7\u2013H3: An attractive target for antibody-based immunotherapy. Clin Cancer Res. 2021;27(5):1227\u201335.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2672_CR90","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1158\/1535-7163.MCT-21-0554","volume":"21","author":"M Yamato","year":"2022","unstructured":"Yamato M, Hasegawa J, Maejima T, Hattori C, Kumagai K, Watanabe A, et al. DS-7300a, a DNA topoisomerase I inhibitor, Dxd-based antibody-drug conjugate targeting B7\u2013H3, exerts potent antitumor activities in preclinical models. Mol Cancer Ther. 2022;21(4):635\u201346.","journal-title":"Mol Cancer Ther"},{"issue":"22","key":"2672_CR91","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1158\/0008-5472.CAN-23-4099","volume":"84","author":"ZZ Zhou","year":"2024","unstructured":"Zhou ZZ, Si Y, Zhang J, Chen K, George A, Kim S, et al. A dual-payload antibody-drug conjugate targeting CD276\/B7-H3 elicits cytotoxicity and immune activation in triple-negative breast cancer. Cancer Res. 2024;84(22):3848\u201363.","journal-title":"Cancer Res"},{"issue":"3","key":"2672_CR92","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","volume":"31","author":"NA Vitanza","year":"2025","unstructured":"Vitanza NA, Ronsley R, Choe M, Seidel K, Huang W, Rawlings-Rhea SD, et al. Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. Nat Med. 2025;31(3):861\u20138.","journal-title":"Nat Med"},{"issue":"1","key":"2672_CR93","doi-asserted-by":"publisher","first-page":"6222","DOI":"10.1038\/s41467-024-50251-x","volume":"15","author":"M Tian","year":"2024","unstructured":"Tian M, Wei JS, Cheuk AT, Milewski D, Zhang Z, Kim YY, et al. CAR t-cells targeting FGFR4 and CD276 simultaneously show potent antitumor effect against childhood rhabdomyosarcoma. Nat Commun. 2024;15(1):6222.","journal-title":"Nat Commun"},{"issue":"8","key":"2672_CR94","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, et al. CAR T Cells Targeting B7\u2013H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. Clin Cancer Res. 2019;25(8):2560\u201374.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2672_CR95","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1158\/1535-7163.MCT-23-0221","volume":"22","author":"MKM Aasted","year":"2023","unstructured":"Aasted MKM, Groen AC, Keane JT, Dabelsteen S, Tan E, Schnabel J, et al. Targeting solid cancers with a cancer-specific monoclonal antibody to surface expressed aberrantly o-glycosylated proteins. Mol Cancer Ther. 2023;22(10):1204\u201314.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"2672_CR96","doi-asserted-by":"publisher","first-page":"102350","DOI":"10.1016\/j.xcrm.2025.102350","volume":"6","author":"R Abrantes","year":"2025","unstructured":"Abrantes R, Forcados C, Warren DJ, Santos-Ferreira L, Fleten KG, Senra E, et al. Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumors. Cell Reports Medicine. 2025;6(9):102350.","journal-title":"Cell Reports Medicine"},{"key":"2672_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-025-01971-8","author":"R Hurtado-Guerrero","year":"2025","unstructured":"Hurtado-Guerrero R, Gatos S, Gines-Alcober I, Macias-Leon J, Gonzalez-Ramirez AM, Kasapoglu I, et al. Structure-guided phage display discovery of antibodies for (S)Tn-glycans in protein context. Nat Chem Biol. 2025. https:\/\/doi.org\/10.1038\/s41589-025-01971-8.","journal-title":"Nat Chem Biol"},{"issue":"1","key":"2672_CR98","doi-asserted-by":"publisher","first-page":"12196","DOI":"10.1038\/s41598-018-30421-w","volume":"8","author":"LR Loureiro","year":"2018","unstructured":"Loureiro LR, Sousa DP, Ferreira D, Chai W, Lima L, Pereira C, et al. Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2-6 sialic acids. Sci Rep. 2018;8(1):12196.","journal-title":"Sci Rep"},{"issue":"7","key":"2672_CR99","doi-asserted-by":"publisher","first-page":"e1171434","DOI":"10.1080\/2162402X.2016.1171434","volume":"5","author":"C Sedlik","year":"2016","unstructured":"Sedlik C, Heitzmann A, Viel S, Ait Sarkouh R, Batisse C, Schmidt F, et al. Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen. Oncoimmunology. 2016;5(7):e1171434.","journal-title":"Oncoimmunology"},{"issue":"1","key":"2672_CR100","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13048-024-01397-1","volume":"17","author":"L Al-Alem","year":"2024","unstructured":"Al-Alem L, Prendergast JM, Clark J, Zarrella B, Zarrella DT, Hill SJ, et al. Sialyl-Tn serves as a potential therapeutic target for ovarian cancer. J Ovarian Res. 2024;17(1):71.","journal-title":"J Ovarian Res"},{"issue":"14","key":"2672_CR101","doi-asserted-by":"publisher","first-page":"10088","DOI":"10.1021\/acsnano.3c12487","volume":"18","author":"R Freitas","year":"2024","unstructured":"Freitas R, Ferreira E, Miranda A, Ferreira D, Relvas-Santos M, Castro F, et al. Targeted and self-adjuvated nanoglycovaccine candidate for cancer immunotherapy. ACS Nano. 2024;18(14):10088\u2013103.","journal-title":"ACS Nano"},{"key":"2672_CR102","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jconrel.2024.01.065","volume":"367","author":"R Freitas","year":"2024","unstructured":"Freitas R, Miranda A, Ferreira D, Relvas-Santos M, Castro F, Ferreira E, et al. A multivalent CD44 glycoconjugate vaccine candidate for cancer immunotherapy. J Control Release. 2024;367:540\u201356.","journal-title":"J Control Release"},{"issue":"5","key":"2672_CR103","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00262-020-02503-0","volume":"69","author":"P Rosenbaum","year":"2020","unstructured":"Rosenbaum P, Artaud C, Bay S, Ganneau C, Campone M, Delaloge S, et al. The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients. Cancer Immunol Immunother. 2020;69(5):703\u201316.","journal-title":"Cancer Immunol Immunother"},{"issue":"D1","key":"2672_CR104","doi-asserted-by":"publisher","first-page":"D1523","DOI":"10.1093\/nar\/gkaa1012","volume":"49","author":"Y Watanabe","year":"2021","unstructured":"Watanabe Y, Aoki-Kinoshita KF, Ishihama Y, Okuda S. Glycopost realizes FAIR principles for glycomics mass spectrometry data. Nucleic Acids Res. 2021;49(D1):D1523\u20138.","journal-title":"Nucleic Acids Res"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-02672-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02672-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02672-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T13:03:38Z","timestamp":1770987818000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-02672-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":104,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2672"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-02672-y","relation":{"references":[{"id-type":"doi","id":"10.1042\/BSR20191062","asserted-by":"subject"}]},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"21 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Human peripheral T cells were isolated from buffy coats of healthy donors obtained from the Immunochemotherapy Department of Centro Hospitalar S\u00e3o Jo\u00e3o (CHSJ), Porto, Portugal. All procedures were conducted with informed consent and approved by the institutional ethics committee (Protocol reference 260\/11). All procedures with clinical tissue samples were conducted in compliance with institutional ethical guidelines and approved by the IPO Porto Ethics Committee (project reference: CES 86\/017). Written informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JAF is the founder and CEO of GlycoMatters Biotech. LLS and AMNS are also founders of the company.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"113"}}